Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active
Document Type
Article
Publication Date
3-1-2026
Abstract
Objective: This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment. Methods: Patients in a multinational cohort with SLE who had clinical disease activity but were not in LLDAS or DORIS were observed prospectively. Results: A total of 1,991 patients (93.2% female) were observed for a median (interquartile range) of 2.5 (0.7–4.5) years, with 70.9% and 55.6% achieving LLDAS and DORIS, respectively. Nephritis and low complements were associated with a longer time, and antimalarial and immunosuppressant use were associated with a shorter time to LLDAS attainment. After the first LLDAS and DORIS attainment, 47.0% and 47.5% of the patients experienced flare(s), respectively, and 9.5% and 7.9 % of patients accrued organ damage within 24 months, respectively. Longer cumulative time at target and antimalarial use was associated with a longer time to flare and damage accrual, whereas dose reduction in glucocorticoids and immunosuppressants was associated with a shorter time to flare. Reduction in immunosuppressants also correlated with a shorter time to damage accrual. Conclusion: In patients with SLE with clinical disease activity, the proportion attaining LLDAS and DORIS under usual care conditions is suboptimal. Longer maintenance of these states is significantly associated with reduced risk of flare. Because flares and damage accrual still occur frequently following initial target attainment, further research is needed to inform strategies for maintaining these targets.
Keywords
Adult; Antimalarials; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Middle Aged; Prevalence; Prospective Studies; Remission Induction; Severity of Illness Index; Symptom Flare Up; Time Factors; Treatment Outcome
Publication Title
Arthritis Care and Research
ISSN
2151-464X
DOI
10.1002/acr.25640
Recommended Citation
Hao, Yanjie; Hansen, Dylan; Kandane-Rathnayake, Rangi; Louthrenoo, Worawit; Chen, Yi Hsing; Cho, Jiacai; Lateef, Aisha; Hamijoyo, Laniyati; Luo, Shue Fen; Wu, Yeong Jian Jan; Navarra, Sandra; Zamora, Leonid; Li, Zhanguo; Sockalingam, Sargunan; Katsumata, Yasuhiro; Harigai, Masayoshi; Zhang, Zhuoli; and Chan, Madelynn, "Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active" (2026). Research Publications (2026 to 2030). 1214.
https://knova.um.edu.my/research_publications_2026_2030/1214
Funders
National Research Foundation of Korea, University of Sydney, University of Melbourne, APLC, Australian University Librarians, AstraZeneca, Ministry of Education (NRF‐2021R1A6A1A03038899), National Health and Medical Research Council (GNT1176538)
Volume
78
Issue
3
First Page
378
Last Page
387
Publisher
John Wiley and Sons Inc